曲尼司特钠  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:10mg 50mg in glass bottle
产品描述:基本信息 产品编号: T10846 产品名称: Tranilast sodium CAS: 104931-56-8   储存条件 粉末 -20℃ 四年 分子式: C18H16NNaO5 溶于液体 -80℃ 二年 分子量 349.31     化学名:  sodium;2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoate Solubility (25°C):   体外:   DMSO   Ethanol   Water   体内(现配现用):   <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。   生物活性 产品描述 一种抗变态反应剂。抑制前列腺素 D2 产生 (PGD2,IC50=0.1mM)。具有抗炎和免疫调节作用。Tranilast sodium 拮抗血管紧张素 II (angiotensin II) 并抑制其在血管平滑肌细胞中的生物学作用。 靶点 PGD2 0.1mM (IC50) Angiotensin II   体外研究 Tranilast exhibits significant immunomodulatory activity inhibiting Endotoxin-induced prostaglandin E2 (PGE2;IC50=~1-20μM),thromboxane B2 (IC50=~10-50μM),(TGF-β1;IC50=~100-200μM),and IL-8 (IC50=~100μM) formation.A23187-induced monocyte leukotriene C4 or PGE2 formation is inhibited by Tranilast at IC50s of 10-40μM and 2-20μM,respectively.Tranilast (10-200μM) exhibits the anti-proliferative effect in a dose-dependent manner in both MCF-7 and MDA-MB-231 cell lines.Tranilast also (10-200μM) enhances the anti-tumor effects of Tamoxifen (1-20μM) on human breast cancer cells in vitro.Tranilast (12.5,25,50,100μg/mL;72 hours) inhibits proliferation of HDMECs.Cell Proliferation Assay Cell Line: MCF-7 and MDA-MB-231 cells Concentration: 10,20,50,100,and 200μM Incubation Time: 48 hours Result: Anti-proliferative effect in a dose-dependent manner in both cell lines. Cell Proliferation Assay Cell Line: Human dermal microvascular endothelial cells (HDMECs) Concentration: 12.5,25,50,100μg/mL Incubation Time: 72 hours Result: IC50 value was 44.3μg/mL (136μM). 体内研究 Tranilast (300mg/kg;administered orally twice a day for 3 days) dose-dependently suppresses angiogenesis in mice. Animal Model: Nine-week-old male C57BL/6 mice Dosage: 300mg/kg Administration: Administered orally twice a day for 3 days Result: Suppressed the VEGF-induced angiogenesis in matrigel;58% of significant suppression was observed at a dose of 300mg/kg.The ED50 value and 95% confidence limits were 165mg/kg and 162±169mg/kg,respectively.
保存条件:-20℃